Cdex Inc Cl A (CDEX) 0.0027 $CDEX
CDEX Granted New Patent for Chemical and Molecular Identification and Quantification System Utilizing Enhanced Photoemission Spectroscopy
Marketwired - Wed Apr 22, 7:30AM CDT
CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that the United States Patent and Trademark Office has granted the Company U.S. Patent 9,013,686 B2, relating to the methods for identification and determination of unknown substances using Enhanced Photoemission Spectroscopy.
CDEX Inc. Issues Shareholder Update Letter
Marketwired - Mon Jan 12, 7:30AM CST
CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that it has posted to its corporate website a letter to its shareholders. In the letter, Jeffrey Brumfield, Chairman and CEO of CDEX, discusses the events of 2014 and provides insight into the upcoming year.
CDEX Secures $430,000 Line of Credit
Marketwired - Mon Oct 20, 7:30AM CDT
CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that it has secured an aggregate $430,000 line of credit from the Company's CEO, Jeffrey Brumfield, and one of CDEX's largest shareholders. Funds drawn against the line will be used for general working capital purposes and to support the manufacturing and marketing of the ValiMed(TM) G4 system, the Company's next generation medication validation system designed and engineered specifically to address and mitigate drug diversion in the healthcare industry -- a market estimated by the National Drug Intelligence Center to cost public and private medical insurers $72.5 billion each year.
CDEX Granted New Patent for Chemical and Molecular Identification and Quantification System Utilizing Enhanced Photoemission Spectroscopy
Marketwired - Wed Apr 22, 7:30AM CDT
CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that the United States Patent and Trademark Office has granted the Company U.S. Patent 9,013,686 B2, relating to the methods for identification and determination of unknown substances using Enhanced Photoemission Spectroscopy.
CDEX Inc. Issues Shareholder Update Letter
Marketwired - Mon Jan 12, 7:30AM CST
CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that it has posted to its corporate website a letter to its shareholders. In the letter, Jeffrey Brumfield, Chairman and CEO of CDEX, discusses the events of 2014 and provides insight into the upcoming year.
CDEX Secures $430,000 Line of Credit
Marketwired - Mon Oct 20, 7:30AM CDT
CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that it has secured an aggregate $430,000 line of credit from the Company's CEO, Jeffrey Brumfield, and one of CDEX's largest shareholders. Funds drawn against the line will be used for general working capital purposes and to support the manufacturing and marketing of the ValiMed(TM) G4 system, the Company's next generation medication validation system designed and engineered specifically to address and mitigate drug diversion in the healthcare industry -- a market estimated by the National Drug Intelligence Center to cost public and private medical insurers $72.5 billion each year.
